WARSAW — Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, is pleased to announce an expanded safety claim from the U.S. Food and Drug Administration for Gel-One® Cross-linked Hyaluronate, indicating that this single-injection viscosupplement for the knee joint is safe for use in repeat treatments.   Gel-One Hyaluronate is administered in the physician …read more.